Franklin Resources Inc. Has $15.57 Million Holdings in Aura Biosciences, Inc. (NASDAQ:AURA)

Franklin Resources Inc. lifted its stake in shares of Aura Biosciences, Inc. (NASDAQ:AURA - Free Report) by 14.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,668,960 shares of the company's stock after purchasing an additional 215,597 shares during the period. Franklin Resources Inc. owned approximately 3.34% of Aura Biosciences worth $15,571,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the stock. Barclays PLC lifted its stake in shares of Aura Biosciences by 256.5% during the third quarter. Barclays PLC now owns 61,010 shares of the company's stock valued at $544,000 after acquiring an additional 43,897 shares during the period. Geode Capital Management LLC raised its holdings in Aura Biosciences by 4.1% during the 3rd quarter. Geode Capital Management LLC now owns 1,008,827 shares of the company's stock worth $8,990,000 after purchasing an additional 39,379 shares during the last quarter. Wellington Management Group LLP acquired a new position in Aura Biosciences during the 3rd quarter valued at about $1,037,000. State Street Corp boosted its stake in shares of Aura Biosciences by 3.7% in the 3rd quarter. State Street Corp now owns 754,803 shares of the company's stock valued at $6,725,000 after purchasing an additional 26,841 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in shares of Aura Biosciences by 2.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 138,356 shares of the company's stock worth $1,233,000 after buying an additional 3,612 shares during the period. 96.75% of the stock is owned by institutional investors.

Aura Biosciences Stock Up 1.1 %

Shares of AURA traded up $0.09 on Friday, hitting $8.20. The company's stock had a trading volume of 612,493 shares, compared to its average volume of 182,930. The firm's fifty day moving average price is $9.69 and its 200-day moving average price is $8.78. Aura Biosciences, Inc. has a fifty-two week low of $6.63 and a fifty-two week high of $12.38. The firm has a market capitalization of $409.60 million, a price-to-earnings ratio of -4.74 and a beta of 0.26.

Aura Biosciences (NASDAQ:AURA - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.42) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.02. As a group, equities analysts predict that Aura Biosciences, Inc. will post -1.66 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

AURA has been the topic of a number of recent research reports. HC Wainwright reaffirmed a "buy" rating and issued a $22.00 price objective on shares of Aura Biosciences in a research note on Thursday, November 14th. Evercore ISI raised Aura Biosciences to a "strong-buy" rating in a research note on Monday, September 16th. Scotiabank upped their price objective on Aura Biosciences from $20.00 to $23.00 and gave the company a "sector outperform" rating in a report on Friday, October 18th. Lifesci Capital upgraded Aura Biosciences to a "strong-buy" rating in a research report on Monday, September 9th. Finally, BTIG Research increased their price target on shares of Aura Biosciences from $21.00 to $24.00 and gave the company a "buy" rating in a research report on Friday, October 18th. Five equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus target price of $23.00.

Insider Buying and Selling

In other Aura Biosciences news, insider Janet Jill Hopkins sold 11,822 shares of the business's stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $9.36, for a total value of $110,653.92. Following the sale, the insider now owns 151,693 shares in the company, valued at approximately $1,419,846.48. The trade was a 7.23 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Los Pinos Elisabet De sold 24,992 shares of the company's stock in a transaction that occurred on Friday, October 18th. The stock was sold at an average price of $12.04, for a total value of $300,903.68. Following the transaction, the insider now directly owns 329,847 shares of the company's stock, valued at approximately $3,971,357.88. This trade represents a 7.04 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 79,081 shares of company stock valued at $891,353. Company insiders own 5.40% of the company's stock.

Aura Biosciences Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.